Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Leukocyte telomere length predicts cancer risk in Barrett's esophagus.

Risques RA, Vaughan TL, Li X, Odze RD, Blount PL, Ayub K, Gallaher JL, Reid BJ, Rabinovitch PS.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2649-55.

2.

Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.

Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ; Probar-study Group.

Gastroenterology. 2011 Dec;141(6):2000-8; quiz e13-4. doi: 10.1053/j.gastro.2011.08.036. Epub 2011 Aug 28.

PMID:
21878200
3.

The impact of lifestyle on Barrett's Esophagus: A precursor to esophageal adenocarcinoma.

Navab F, Nathanson BH, Desilets DJ.

Cancer Epidemiol. 2015 Dec;39(6):885-91. doi: 10.1016/j.canep.2015.10.013. Epub 2015 Nov 9.

PMID:
26519660
4.

Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.

Gaddam S, Singh M, Balasubramanian G, Thota P, Gupta N, Wani S, Higbee AD, Mathur SC, Horwhat JD, Rastogi A, Young PE, Cash BD, Bansal A, Vargo JJ, Falk GW, Lieberman DA, Sampliner RE, Sharma P.

Gastroenterology. 2013 Sep;145(3):548-53.e1. doi: 10.1053/j.gastro.2013.05.040. Epub 2013 May 25.

PMID:
23714382
5.

Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort.

Hardikar S, Onstad L, Song X, Wilson AM, Montine TJ, Kratz M, Anderson GL, Blount PL, Reid BJ, White E, Vaughan TL.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2393-403. doi: 10.1158/1055-9965.EPI-14-0384. Epub 2014 Aug 8.

6.

Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.

Chao DL, Maley CC, Wu X, Farrow DC, Galipeau PC, Sanchez CA, Paulson TG, Rabinovitch PS, Reid BJ, Spitz MR, Vaughan TL.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1935-40.

7.

Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma.

Duggan C, Onstad L, Hardikar S, Blount PL, Reid BJ, Vaughan TL.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):934-43. doi: 10.1016/j.cgh.2013.02.017. Epub 2013 Mar 1.

8.

Barrett's surveillance identifies patients with early esophageal adenocarcinoma.

Wong T, Tian J, Nagar AB.

Am J Med. 2010 May;123(5):462-7. doi: 10.1016/j.amjmed.2009.10.013.

PMID:
20399324
9.

Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium.

Gopal DV, Lieberman DA, Magaret N, Fennerty MB, Sampliner RE, Garewal HS, Falk GW, Faigel DO.

Dig Dis Sci. 2003 Aug;48(8):1537-41.

PMID:
12924649
11.

Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.

Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ.

Am J Gastroenterol. 2009 Nov;104(11):2673-80. doi: 10.1038/ajg.2009.437. Epub 2009 Jul 28.

PMID:
19638963
12.

The diagnosis and management of Barrett's esophagus.

DeMeester SR, DeMeester TR.

Adv Surg. 1999;33:29-68. Review.

PMID:
10572561
13.

Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.

Weston AP, Sharma P, Mathur S, Banerjee S, Jafri AK, Cherian R, McGregor D, Hassanein RS, Hall M.

Am J Gastroenterol. 2004 Sep;99(9):1657-66.

PMID:
15330898
14.

Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.

Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, Reid BJ.

Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52.

15.

Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.

Wang F, Lv ZS, Fu YK.

Dis Esophagus. 2011 Jul;24(5):318-24. doi: 10.1111/j.1442-2050.2010.01153.x. Epub 2010 Dec 17. Review.

PMID:
21166737
16.

Barrett's esophagus: a retrospective analysis of 13 years surveillance.

Switzer-Taylor V, Schlup M, Lübcke R, Livingstone V, Schultz M.

J Gastroenterol Hepatol. 2008 Sep;23(9):1362-7. doi: 10.1111/j.1440-1746.2008.05311.x. Epub 2008 Jan 17.

PMID:
18205769
17.

Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, Murray LJ.

J Natl Cancer Inst. 2011 Jul 6;103(13):1049-57. doi: 10.1093/jnci/djr203. Epub 2011 Jun 16. Erratum in: J Natl Cancer Inst. 2013 Apr 17;105(8):581.

18.

Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study.

Solaymani-Dodaran M, Logan RF, West J, Card T.

Am J Gastroenterol. 2005 Dec;100(12):2616-21.

PMID:
16393209
19.

Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.

Goodarzi M, Correa AM, Ajani JA, Swisher SG, Hofstetter WL, Guha S, Deavers MT, Rashid A, Maru DM.

Mod Pathol. 2009 Dec;22(12):1612-21. doi: 10.1038/modpathol.2009.133. Epub 2009 Sep 4.

20.

Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study.

Dong LM, Kristal AR, Peters U, Schenk JM, Sanchez CA, Rabinovitch PS, Blount PL, Odze RD, Ayub K, Reid BJ, Vaughan TL.

Nutr Cancer. 2008;60(1):39-48. doi: 10.1080/01635580701586762.

Items per page

Supplemental Content

Write to the Help Desk